Company (symbol) |
Date filed |
Date comm. |
Shares/Units (M) |
Price |
Shares out (M) |
Lead, other underwriters |
Gross (US$M) |
Post-offering market cap (M) |
|
Initial offerings total: $1,269.72M |
|||||||||
Adial Pharmaceuticals LLC (Charlottesville, Va.; ADIL)1 |
9/12/17 |
7/30/18 |
1.46S |
$5 |
6.54 |
Joseph Gunnar; Dawson James Securities |
$7.32 |
$32.70 |
|
Allakos Inc. (San Carlos, Calif.; ALLK)2 |
6/22/18 |
7/19/18 |
8.2S |
$18.00 |
40.5 |
Goldman Sachs; Jefferies; William Blair |
$128.40 |
$729.00 |
|
Aquestive Therapeutics Inc. (Warren, N.J.; AQST)3 |
6/27/18 |
7/27/18 |
4.5S |
$15 |
24.5 |
BMO Capital Markets; RBC Capital Markets; Wedbush Pacgrow; JMP Securities |
$67.50 |
$367.50 |
|
Ascletis Pharma Inc. (Hangzhou, China; HKEX:1672)4 |
5/10/18 |
7/27/18 |
N/A |
N/A |
N/A |
China Merchants Securities; Goldman Sachs; Morgan Stanley |
$397.50 |
N/A |
|
Constellation Pharmaceuticals Inc. (Cambridge, Mass.; CNST)5 |
6/22/18 |
7/19/18 |
4S |
$15.00 |
25.7 |
J.P. Morgan; Jefferies; BMO Capital Markets; Oppenheimer |
$60.00 |
$385.50 |
|
Crinetics Pharmaceuticals Inc. (San Diego; CRNX)6 |
7/11/18 |
7/19/18 |
6.9S |
$17.00 |
23.9 |
J.P. Morgan Securities; Leerink Partners; Piper Jaffray |
$117.30 |
$406.30 |
|
Liquidia Technologies Inc. (Research Triangle Park, N.C.; LQDA)7 |
6/28/18 |
7/27/18 |
4.54S |
$11 |
15.1 |
Jefferies Group; Cowen; Needham; Wedbush Pacgrow |
$50.00 |
$166.10 |
|
Provention Bio Inc. (Oldwick, N.J.; PRVB) |
5/12/18 |
7/23/18 |
16.375S |
$4.00 |
33.9 |
MDB Capital Group |
$63.90 |
$135.60 |
|
Replimune Group Inc. (Woburn, Mass.; REPL)8 |
6/26/18 |
7/23/18 |
6.7S |
$15.00 |
30.8 |
J.P. Morgan Securities; Leerink Partners; BMO Capital Markets |
$100.50 |
$462.00 |
|
Rubius Therapeutics Inc. (Cambridge, Mass.; RUBY)9 |
6/22/18 |
7/19/18 |
12.05S |
$23.00 |
78.9 |
J.P. Morgan; Morgan Stanley; Jefferies; Leerink Partners |
$277.30 |
$1,814.70 |
|
|
Number of IPOs in July: 10 Average value of July IPOs: $126.97M Number of IPOs in 2018: 49 Total raised in IPOs in 2018: $5,216.43M Average value of IPOs in 2018: $106.46M | |||||||||
Follow-on offerings total: $2,124.46M |
|||||||||
AC Immune SA (Lausanne, Switzerland; ACIU)10 |
6/8/18 |
7/19/18 |
8.49S |
$11.75 |
65.85 |
Jefferies; Leerink Partners; UBS Investment Bank; H.C. Wainwright |
$99.76 |
$773.74 |
|
Acelrx Pharmaceuticals Inc. (Redwood City, Calif.; ACRX)11 |
6/14/18 |
7/11/18 |
7.27S |
$2.75 |
58.26 |
Cantor; H.C. Wainwright |
$20.00 |
$160.22 |
|
Arqule Inc. (Burlington, Mass.; ARQL)12 |
10/5/16 |
7/12/18 |
12.65S |
$5.50 |
99.78 |
Leerink Partners; Needham; Roth Capital Partners; B. Riley FBR; Jonestrading |
$70.00 |
$548.79 |
|
Assembly Biosciences Inc. (San Francisco; ASMB)13 |
1/10/18 |
7/10/18 |
4.6S |
$36.00 |
25 |
Jefferies; Leerink Partners; William Blair; Mizuho Securities; Baird |
$165.60 |
$900.00 |
|
Bluebird Bio Inc. (Cambridge, Mass.; BLUE)14 |
2/22/17 |
7/31/18 |
3.89S |
$162.50 |
53.96 |
Goldman Sachs; Bofa Merrill Lynch; J.P. Morgan Securities; Cowen; Wells Fargo Securities |
$632.50 |
$8,768.50 |
|
Cara Therapeutics Inc. (Stamford, Conn.; CARA)15 |
3/24/17 |
7/20/18 |
5.17S |
$19.00 |
39 |
Jefferies; Bofa Merrill Lynch; Piper Jaffray; Stifel; Canaccord Genuity; Needham; H.C. Wainwright; Janney Montgomery Scott |
$98.30 |
$741.00 |
|
Cellectar Biosciences Inc. (Madison, Wis.; CLRB)16 |
7/30/18 |
7/30/18 |
1.35S |
$4.00 |
2.62 |
Ladenburg Thalmann; CIM Securities |
$16.56 |
$10.48 |
|
Contrafect Corp. (Yonkers, N.Y.; CFRX)17 |
5/25/17 |
7/30/18 |
5S |
$2.00 |
78.66 |
Piper Jaffray; William Blair; Chardan |
$10.00 |
$157.32 |
|
Cytomx Therapeutics Inc. (South San Francisco; CTMX)18 |
12/7/16 |
7/10/18 |
5.1S |
$24.50 |
43.9 |
Goldman Sachs; Citigroup; Barclays |
$125.00 |
$1,075.55 |
|
Evolus Inc. (Irvine, Calif.; EOLS)19 |
7/18/18 |
7/20/18 |
3S |
$20.00 |
26.64 |
Cantor Fitzgerald; Mizuho Securities USA; Suntrust Robinson Humphrey; JMP Securities |
$60.00 |
$532.80 |
|
Intrexon Corp. (Germantown, Md.; XON)20 |
9/1/17 |
7/2/18 |
Notes |
$1,000.00 |
136.7 |
J.P. Morgan |
$200.00 |
$1,827.68 |
|
Myovant Sciences Ltd. (Basel, Switzerland; MYOV)21 |
3/23/18 |
7/11/18 |
3.3S |
$22.50 |
64.33 |
J.P. Morgan; Goldman Sachs; Barclays; JMP Securities; Baird |
$75.00 |
$1,447.43 |
|
Nabriva Therapeutics plc (Dublin: NBRV)22 |
4/27/18 |
7/30/18 |
18.18S |
$2.75 |
66.48 |
Morgan Stanley; Bofa Merrill Lynch; Suntrust Robinson Humphrey; Needham; Wedbush Securities |
$50.00 |
$182.82 |
|
Oragenics Inc. (Tampa, Fla.; NYSE:OGEN)23 |
7/13/18 |
7/16/18 |
2.6U and 9.4U |
$1.00 |
8.74 |
Cowen; Stifel; Nicolaus; Cantor Fitzgerald; Ladenburg Thalmann |
$13.80 |
N/A |
|
Reata Pharmaceuticals Inc. (Irving, Texas; RETA)24 |
7/23/18 |
7/26/18 |
3.45S |
$72.00 |
29.67 |
Jefferies; Leerink Partners; Stifel, Nicolaus; Cantor Fitzgerald; Ladenburg Thalmann |
$248.40 |
$2,136.24 |
|
Savara Inc. (Austin, Texas; SVRA)25 |
7/13/18 |
7/26/18 |
4.25S |
$11.50 |
34.85 |
Jefferies; Evercore Group; Canaccord Genuity; JMP Securities; H.C. Wainwright |
$48.90 |
$400.78 |
|
Sellas Life Sciences Group Inc. (New York; NYSE:SLS) |
6/27/18 |
7/12/18 |
11.52S and W for 11.2S |
$2.10 |
17.67 |
Cantor Fitzgerald; Oppenheimer; Maxim Group |
$24.20 |
$37.11 |
|
Spero Therapeutics Inc. (Cambridge, Mass.; SPRO)26 |
7/11/18 |
7/16/18 |
3.8S and preferred stock |
$12.50 |
17.6 |
Cowen; Stifel, Nicolaus & Co.; Cantor Fitzgerald; Oppenheimer; H.C. Wainwright |
$75.00 |
$220.00 |
|
Veracyte Inc. (South San Francisco; VCYT)27 |
5/11/18 |
7/31/18 |
5.75S |
$10.25 |
40.19 |
BTIG; Leerink Partners; William Blair |
$58.94 |
$411.95 |
|
Zynerba Pharmaceuticals Inc. (Devon, Pa.; ZYNE)28 |
6/22/17 |
7/20/18 |
4.06S |
$8.00 |
17.62 |
Cantor |
$32.50 |
$140.96 |
|
|
Number of follow-ons in July: 20 Average value of July follow-ons: $106.2M Number of follow-ons in 2018: 166 Total raised in follow-ons in 2018: $22,098.68M Average value of follow-ons in 2018: $133.12M | |||||||||
|
Notes Unless otherwise indicated, shares are traded on the Nasdaq exchange. Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. This chart includes only biopharma companies that develop therapeutics. HKEX = Hong Kong Stock Exchange. 1 Adial's overallotment option: 225,000 shares. 2 Includes Allakos' overallotment option: 1.07M shares. 3 Aquestive's overallotment option: 675,000 shares. 4 Ascletis' overallotment option: 10% of shares. Company raised HK$3.12B (US$397.5M) 5 Constellation's overallotment option: 600,000 shares. 6 Includes Crinetics' overallotment option: 900,000 shares. 7 Liquidia's overallotment option: 681,818 shares. 8 Relimune's overallotment option: 1.005M shares. 9 Rubius' overallotment option: 1.57M shares. 10 Includes AC Immune's overallotment option: 1.1M shares. 11 Acelrx' overallotment option: 1.09M additional shares. 12 Includes Arqule's overallotment option: 1.65M shares. 13 Includes Assembly's overallotment option: 600,000 shares. 14 Includes Bluebird's overallotment option: 507,692 shares. 15 Includes Cara's overallotment option: 675,000 shares. 16 Cellectar's offering is priced at $4 per common share, with each common share including a five-year series E warrant to purchase one share of common stock with an exercise price of $4 per share. The company also issued 1,114 shares of series C convertible preferred stock. Overallotment option: 540,000 additional shares of common stock and warrants. 17 Contrafect's offering: 750,000 shares. 18 Cytomx' overallotment option: 765,306 shares. 19 Evolus' offering includes 3M shares offered by the company and another 1M shares offered by a selling stockholder. Overallotment option: 600,000 shares. 20 Intrexon sold $200M of its convertible senior notes due 2023. Overallotment option: $30M in notes. 21 Myovant's overallotment option: 500,000 shares. 22 Nabriva's overallotment option: 2.72M shares. 23 Oragenics' offering comprises 2.6M class A units, each consisting of one share and a seven-year warrant to purchase another share, and 9.4M class B units, each consisting of one share of series D preferred stock and a seven-year warrant to purchase one share. Includes overallotment option: 1.8M shares and/or warrants to purchase up to 1.8M shares. 24 Includes Reata's overallotment option: 450,000 shares. 25 Savara's overallotment option: 637,000 shares. 26 Spero's offering consists of 3.8M shares of common stock and 2,220 shares of its non-voting series A convertible preferred stock, at $12.50 and $12,500 each, respectively. Overallotment option: 567,000 shares. Each share of preferred stock is convertible into 1,000 shares of common stock. 27 Includes Veracyte's overallotment option: 750,000 shares. 28 Zynerba's overallotment option: 609,375 shares. | |||||||||